NCT03850730 is a Phase 1, PHASE2 clinical trial of Pazopanib in Hereditary Hemorrhagic Telangiectasia, sponsored by Cure HHT.

Who is sponsoring NCT03850730?

NCT03850730 is sponsored by Cure HHT.

What drugs are being tested in NCT03850730?

Interventions in NCT03850730: Pazopanib.

What condition does NCT03850730 study?

NCT03850730 studies Hereditary Hemorrhagic Telangiectasia, Epistaxis.

Is NCT03850730 still recruiting?

NCT03850730 is currently status unknown. Last updated 8 September 2022.

Last reviewed 2022-09-08 · How we verify

NCT03850730

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia

Status unknown Phase 1, PHASE2 Last updated 8 September 2022

What this trial tests

Phase 1, PHASE2 trial testing Pazopanib in Hereditary Hemorrhagic Telangiectasia in 30 participants. Status unknown.

Timeline

1 July 2023

Primary endpoint
30 June 2025

31 December 2025

Quick facts

Lead sponsor	Cure HHT
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 July 2023
Primary completion	30 June 2025
Estimated completion	31 December 2025

Drugs / interventions tested

Pazopanib — full drug profile →

Conditions studied

Hereditary Hemorrhagic Telangiectasia — all drugs for Hereditary Hemorrhagic Telangiectasia →
Epistaxis — all drugs for Epistaxis →

Sponsor

Cure HHT

Who can join

Adults 18 to 75, any sex, with Hereditary Hemorrhagic Telangiectasia or Epistaxis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigators will test the value of very low dose Pazopanib administered to patients with hereditary hemorrhagic telangiectasia for the reduction in the severity of nose bleeds in those with frequent and long duration bleeding episodes.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Future treatments for hereditary hemorrhagic telangiectasia.
Robert F, Desroches-Castan A, Bailly S, Dupuis-Girod S, et al · · 2020 · cited 76× · PMID 31910860 · DOI 10.1186/s13023-019-1281-4
Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding.
Albiñana V, Cuesta AM, Rojas-P I, Gallardo-Vara E, et al · · 2020 · cited 20× · PMID 32517280 · DOI 10.3390/jcm9061766
Vascular malformations: An overview of their molecular pathways, detection of mutational profiles and subsequent targets for drug therapy.
Mansur A, Radovanovic I. · · 2023 · cited 14× · PMID 36846125 · DOI 10.3389/fneur.2023.1099328
Pathophysiology in Brain Arteriovenous Malformations: Focus on Endothelial Dysfunctions and Endothelial-to-Mesenchymal Transition.
Jeong JY, Bafor AE, Freeman BH, Chen PR, et al · · 2024 · cited 6× · PMID 39200259 · DOI 10.3390/biomedicines12081795
Targeted medical therapies for vascular anomalies.
Borst A. · · 2024 · cited 1× · PMID 39644074 · DOI 10.1182/hematology.2024000599
Vascular malformations: from genetics to therapeutics.
Morin G, Galasso I, Canaud G. · · 2026 · PMID 41272322 · DOI 10.1038/s44321-025-00344-x
Epistaxis Prevention, Treatment, and Future Perspectives for Hereditary Hemorrhagic Telangiectasia.
Ficany A, Del Alamo M, Bernabeu C, Shovlin CL, et al · · 2025 · PMID 41227119 · DOI 10.3390/jcm14217724
Pathogenesis and therapy of arteriovenous malformations: A case report and narrative review.
Tessier S, Lipton BA, Ido F, Longo S, et al · · 2021 · PMID 34760664 · DOI 10.4103/ijciis.ijciis_127_20

Verify or expand the search:

Other trials of Pazopanib

Trials testing the same drug.

NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07087158 — A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT04199026 — Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sa · NA · recruiting
NCT05432791 — Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped W · Phase 2, PHASE3 · active not recruiting
NCT02203760 — Pazopanib Vs. Pazopanib Plus Gemcitabine · Phase 2 · active not recruiting

Other recruiting trials for Hereditary Hemorrhagic Telangiectasia

Currently open trials in the same condition.

NCT06659640 — A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) · Phase 1, PHASE2 · recruiting
NCT04874558 — Ultra-low-dose Chest CT for HHT · active not recruiting
NCT04404881 — Bevacizumab In Hereditary Hemorrhagic Telangiectasia · Phase 2 · active not recruiting
NCT04469517 — Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia · recruiting
NCT04150822 — CHORUS - Comprehensive HHT Outcomes Registry of the United States (Formerly OUR HHT Registry) · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03850730 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cure HHT
Last refreshed: 8 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03850730.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing